The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Kidney Transplant Rejection Market Change Between 2026 And 2030?

The market size for kidney transplant rejection has experienced substantial growth in recent years. This market is expected to expand from $3.51 billion in 2025 to $3.76 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.2%. The historical growth in this sector is attributable to an increase in kidney transplant procedures, progress in histopathological assessment techniques, the broader availability of immunosuppressive drugs, the expansion of transplant center networks, and improved patient survival rates post-transplant.

The kidney transplant rejection market is anticipated to show substantial growth over the next few years, set to reach $5.01 billion in 2030, at a compound annual growth rate (CAGR) of 7.4%. This projected expansion during the forecast period is driven by factors such as an escalating demand for personalized immunosuppression strategies, increased adoption of molecular diagnostics, the expansion of precision medicine within transplant care, a growing emphasis on long-term graft survival, and rising investment in transplant monitoring technologies. Key trends during this period will encompass the increasing integration of biomarker-based rejection monitoring, a rising utilization of genomics-based diagnostic approaches, continuous optimization of immunosuppressive therapy protocols, the development of non-invasive rejection surveillance methods, and an enhanced focus on the early detection of chronic rejection.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33190&type=smp

Which Strategic Drivers Are Supporting The Kidney Transplant Rejection Market Development?

The increasing occurrence of end-stage renal disease is projected to stimulate the expansion of the kidney transplant rejection market in the future. End-stage renal disease (ESRD) is defined as the ultimate, irreversible stage of chronic kidney disease where kidneys are unable to function adequately without external support like dialysis or a kidney transplant. The rise in end-stage renal disease cases is attributed to the growing prevalence of chronic conditions, notably diabetes and hypertension, which progressively damage the kidneys, leading to their failure. Kidney transplant rejection creates a demand for advanced monitoring and therapeutic interventions, directly supporting the effective management of end-stage renal disease by ensuring the continued functionality of transplanted kidneys and preserving patients’ kidney health. For instance, in September 2024, information from the National Institute of Diabetes and Digestive and Kidney Diseases, a US-based government institute, indicated that in 2023, more than 808,000 people in the United States were living with end-stage kidney disease (ESKD), also known as end-stage renal disease (ESRD), with 68% undergoing dialysis and 32% having received a kidney transplant. Therefore, the growing incidence of end-stage renal disease is fueling the growth of the kidney transplant rejection market.

Which Segment-Based Categories Are Covered In The Kidney Transplant Rejection Market?

The kidney transplant rejection market covered in this report is segmented –

1) By Rejection Type: Chronic Rejection; Acute Rejection

2) By Treatment: Immunosuppressive Drugs; Antibody-Mediated Rejection Therapies

3) By Diagnostic Approach: Biomarker-Based Diagnostics; Genomics-Based Diagnostics

4) By Therapeutics: Small Molecule Inhibitors; Biologic Therapies

5) By End-Users: Transplant Centers Or Hospitals; Diagnostic Laboratories; Pharmacies

Subsegments:

1) By Chronic Rejection: Antibody Mediated Chronic Rejection; Chronic Allograft Nephropathy; Interstitial Fibrosis And Tubular Atrophy; Vascular Chronic Rejection; Mixed Chronic Rejection

2) By Acute Rejection: Cellular Acute Rejection; Antibody Mediated Acute Rejection; Hyperacute Rejection; Mixed Acute Rejection; Vascular Acute Rejection

Which Trends Are Influencing The Direction Of The Kidney Transplant Rejection Market?

Leading firms within the kidney transplant rejection market are prioritizing the creation of advanced diagnostic options, including noninvasive urinary biomarker testing, aiming for swifter, safer, and more precise identification of transplant rejection. This noninvasive method examines urine specimens to pinpoint molecular markers signaling kidney inflammation or rejection, thereby assisting medical professionals in promptly and safely recognizing transplant complications, eliminating the necessity for invasive biopsies. An example of this is the launch in May 2024 by Thermo Fisher Scientific Inc., a US-based biotechnology company, of its CXCL10 testing service, representing an innovative diagnostic instrument for individuals who have received kidney transplants. The CXCL10 test identifies the CXCL10 chemokine present in urine, a substance linked to the early stages of transplant rejection and inflammation. This test provides results within 24 hours, facilitating faster clinical judgments, lessening the requirement for superfluous biopsies, and enhancing patient ease through its noninvasive sample collection process. Developed and validated by Thermo Fisher’s One Lambda Laboratories, this assay offers a combination of high sensitivity, specificity, and user-friendliness in clinical environments, thereby contributing to superior post-transplant management and improved patient results.

Which Companies Are Engaged In The Kidney Transplant Rejection Market Environment?

Major companies operating in the kidney transplant rejection market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., ChugAI Pharmaceutical Co. Ltd., Eurofins Scientific SE, Illumina Inc., Natera Inc., CareDx Inc., Azurity Pharmaceuticals Inc., Insight Molecular Diagnostics, and RenalytixAI plc.

Access The Complete Kidney Transplant Rejection Market Report:

https://www.thebusinessresearchcompany.com/report/kidney-transplant-rejection-market-report

Which Region Contributes The Most To The Kidney Transplant Rejection Market?

North America was the largest region in the kidney transplant rejection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney transplant rejection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Kidney Transplant Rejection Market Report for Deeper Competitive Insights

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model